Gan & Lee Pharmaceuticals announced that its insulin aspart injection, developed in collaboration with a local pharmaceutical company in Argentina, has received approval from the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica, ANMAT. This approval marks another key milestone for the company in Argentina, following the previous approval of insulin glargine, and further enriches the company's product portfolio in the region. According to the latest data from the International Diabetes Federation's (IDF) Diabetes Atlas, Argentina's adult diabetes population surpassed 4.34 million in 2024, with a prevalence rate of 14.1%.
In Argentina, the average annual diabetes-related healthcare expenditure per person is around $3,500, significantly higher than the regional Latin American average. This highlights the critical diabetes burden faced by Argentina, a key healthcare market in Latin America. The data highlights the growing demand for high-quality, cost-effective insulin therapies in the country.
To address this pressing need, Gan & Lee has been strategically expanding its presence in the Argentine market, aiming to provide effective solutions. The newly approved insulin aspart injection, with its high-quality formulation, cost-effective pricing, and reliable supply system, is expected to improve the accessibility of diabetes medication for Argentine patients. Notably, Gan & Lee has partnered with local companies for local filling, which will shorten the supply cycle and further strengthen the product's availability in the Argentine market.
This approach not only supports the company's commitment to ensuring supply but also focuses on ensuring stability, with the goal of creating a reliable and sustainable insulin supply system that allows more patients to receive consistent and ongoing treatment. This successful market entry in Argentina provides strong momentum for the company's strategic expansion across Latin America's growing healthcare markets. Looking ahead, Gan & Lee will continue to uphold its patient-centric philosophy and work tirelessly to enhance the global accessibility of high-quality, innovative medicines, ensuring that patients in diverse regions can benefit from better diabetes treatment solutions.
